Guzman MG, Halstead SB, Artsob H, Buchy P, Farrar J, Gubler DJ, Hunsperger E, Kroeger A, Margolis HS, Martinez E, Nathan MB, Pelegrino JL, Simmons C, Yoksan S, Peeling RW, 2010. Dengue: a continuing global threat. Nat Rev Microbiol 8: S7–S16.
Halstead SB, 2003. Neutralization and antibody-dependent enhancement of dengue viruses. Adv Virus Res 60: 421–467.
Hammond SN, Balmaseda A, Perez L, Tellez Y, Saborio SI, Mercado JC, Videa E, Rodriguez Y, Perez MA, Cuadra R, Solano S, Rocha J, Idiaquez W, Gonzalez A, Harris E, 2005. Differences in dengue severity in infants, children, and adults in a 3-year hospital-based study in Nicaragua. Am J Trop Med Hyg 73: 1063–1070.
Trent D, Shin J, Hombach J, Knezevic I, Minor P, 2010. WHO Working Group on technical specifications for manufacture and evaluation of dengue vaccines, Geneva, Switzerland, 11–12 May 2009. Vaccine 28: 8246–8255.
Guy B, Saville M, Lang J, 2010. Development of Sanofi Pasteur tetravalent dengue vaccine. Hum Vaccin Sept 16; 6 (9) [Epub ahead of print].
Nisalak A, Endy TP, Nimmannitya S, Kalayanarooj S, Thisayakorn U, Scott RM, Burke DS, Hoke CH, Innis BL, Vaughn DW, 2003. Serotype-specific dengue virus circulation and dengue disease in Bangkok, Thailand from 1973 to 1999. Am J Trop Med Hyg 68: 191–202.
Siegrist CA, 2001. Neonatal and early life vaccinology. Vaccine 19: 3331–3346.
Adkins B, Leclerc C, Marshall-Clarke S, 2004. Neonatal adaptive immunity comes of age. Nat Rev Immunol 4: 553–564.
Gans H, Yasukawa L, Rinki M, DeHovitz R, Forghani B, Beeler J, Audet S, Maldonado Y, Arvin AM, 2001. Immune responses to measles and mumps vaccination of infants at 6, 9, and 12 months. J Infect Dis 184: 817–826.
Siegrist CA, 2003. Mechanisms by which maternal antibodies influence infant vaccine responses: review of hypotheses and definition of main determinants. Vaccine 21: 3406–3412.
Halstead SB, Lan NT, Myint TT, Shwe TN, Nisalak A, Kalyanarooj S, Nimmannitya S, Soegijanto S, Vaughn DW, Endy TP, 2002. Dengue hemorrhagic fever in infants: research opportunities ignored. Emerg Infect Dis 8: 1474–1479.
Halstead SB, O'Rourke EJ, 1977. Antibody-enhanced dengue virus infection in primate leukocytes. Nature 265: 739–741.
Libraty DH, Acosta LP, Tallo V, Segubre-Mercado E, Bautista A, Potts JA, Jarman RG, Yoon IK, Gibbons RV, Brion JD, Capeding RZ, 2009. A prospective nested case-control study of Dengue in infants: rethinking and refining the antibody-dependent enhancement dengue hemorrhagic fever model. PLoS Med 6: e1000171.
Mongkolsapaya J, Dejnirattisai W, Xu XN, Vasanawathana S, Tangthawornchaikul N, Chairunsri A, Sawasdivorn S, Duangchinda T, Dong T, Rowland-Jones S, Yenchitsomanus PT, McMichael A, Malasit P, Screaton G, 2003. Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever. Nat Med 9: 921–927.
Capeding RZ, Brion JD, Caponpon MM, Gibbons RV, Jarman RG, Yoon IK, Libraty DH, 2010. The incidence, characteristics, and presentation of dengue virus infections during infancy. Am J Trop Med Hyg 82: 330–336.
Webster DP, Farrar J, Rowland-Jones S, 2009. Progress towards a dengue vaccine. Lancet Infect Dis 9: 678–687.
Kliks SC, Nimmannitya S, Nisalak A, Burke DS, 1988. Evidence that maternal dengue antibodies are important in the development of dengue hemorrhagic fever in infants. Am J Trop Med Hyg 38: 411–419.
Simmons CP, Chau TN, Thuy TT, Tuan NM, Hoang DM, Thien NT, Lien le B, Quy NT, Hieu NT, Hien TT, McElnea C, Young P, Whitehead S, Hung NT, Farrar J, 2007. Maternal antibody and viral factors in the pathogenesis of dengue virus in infants. J Infect Dis 196: 416–424.
Watanaveeradej V, Endy TP, Samakoses R, Kerdpanich A, Simasathien S, Polprasert N, Aree C, Vaughn DW, Ho C, Nisalak A, 2003. Transplacentally transferred maternal-infant antibodies to dengue virus. Am J Trop Med Hyg 69: 123–128.
Chau TN, Hieu NT, Anders KL, Wolbers M, Lien le B, Hieu LT, Hien TT, Hung NT, Farrar J, Whitehead S, Simmons CP, 2009. Dengue virus infections and maternal antibody decay in a prospective birth cohort study of Vietnamese infants. J Infect Dis 200: 1893–1900.
Pengsaa K, Luxemburger C, Sabchareon A, Limkittikul K, Yoksan S, Chambonneau L, Chaovarind U, Sirivichayakul C, Lapphra K, Chanthavanich P, Lang J, 2006. Dengue virus infections in the first 2 years of life and the kinetics of transplacentally transferred dengue neutralizing antibodies in thai children. J Infect Dis 194: 1570–1576.
Pengsaa K, Yoksan S, Limkittikul K, Wisetsing P, Sirivichayakul C, Hutacharoen P, Chanthavanich P, Sabchareon A, 2003. Maternally transferred neutralising dengue antibodies in Thai infants: a pilot study. Ann Trop Paediatr 23: 159–165.
Pengsaa K, Limkittikul K, Luxemburger C, Yoksan S, Chambonneau L, Ariyasriwatana C, Lapphra K, Chanthavanich P, Lang J, Sabchareon A, 2008. Age-specific prevalence of dengue antibodies in Bangkok infants and children. Pediatr Infect Dis J 27: 461–463.
Shu PY, Chen LK, Chang SF, Yueh YY, Chow L, Chien LJ, Chin C, Lin TH, Huang JH, 2000. Dengue NS1-specific antibody responses: isotype distribution and serotyping in patients with Dengue fever and Dengue hemorrhagic fever. J Med Virol 62: 224–232.
Russell PK, Nisalak A, Sukhavachana P, Vivona S, 1967. A plaque reduction test for dengue virus neutralization antibodies. J Immunol 99: 285–290.
Diggle P, 2004. Analysis of Longitudinal Data. New York, NY: Oxford University Press.
Burke DS, Nisalak A, Johnson DE, Scott RM, 1988. A prospective study of dengue infections in Bangkok. Am J Trop Med Hyg 38: 172–180.
Thomas SJ, Nisalak A, Anderson KB, Libraty DH, Kalayanarooj S, Vaughn DW, Putnak R, Gibbons RV, Jarman R, Endy TP, 2009. Dengue plaque reduction neutralization test (PRNT) in primary and secondary dengue virus infections: how alterations in assay conditions impact performance. Am J Trop Med Hyg 81: 825–833.
|Past two years||Past Year||Past 30 Days|
|Full Text Views||352||118||3|
Maternal dengue antibodies are important in determining the optimal age of dengue vaccination, but no study has quantified the heterogeneity of antibody decay and persistence in infants. We used longitudinal regression methods and survival analysis to measure decay and persistence times of serotype-specific neutralizing antibodies in 139 infants in Bangkok. A biphasic decay pattern was found with half-life times of 24–29 days between birth and 3 months and 44–150 days after 3 months. Atypical decay rates were found in 17% of infants for dengue virus-1 and -4. Median persistence times of plaque reduction neutralization tests > 10 ranged from 6 to 9 months. Persistence times for individuals could not be predicted based on antibody values at birth. Vaccination against dengue before 12 months of age would be ineffective if maternal antibodies at plaque reduction neutralization test levels below 80 interfere with vaccine uptake. Projections of average antibody persistence based on values at birth should be avoided in studies on dengue pathogenesis in infants.
Financial support: The original study that generated the data used in this analysis was funded by Sanofi Pasteur. No funding was used to conduct the analysis for this manuscript.
Authors' addresses: Willem G. van Panhuis, Department of Epidemiology, University of Pittsburgh Graduate School of Public Health, Pittsburgh PA, E-mail: firstname.lastname@example.org. Christine Luxemburger, Sanofi Pasteur, Lyon, France, E-mail: email@example.com. Krisana Pengsaa, Kriengsak Limkittikul, and Arunee Sabchareon, Department of Tropical Pediatrics, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand, E-mails: firstname.lastname@example.org, email@example.com, and firstname.lastname@example.org. Jean Lang, Sanofi Pasteur, Marcy l'Etoile, France, E-mail: email@example.com. Anna P. Durbin, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, E-mail: firstname.lastname@example.org. Derek A. T. Cummings, Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, E-mail: email@example.com.
Reprint requests: Willem G. van Panhuis, Department of Epidemiology, University of Pittsburgh Graduate School of Public Health, 130 DeSoto Street, 704 Parran Hall, Pittsburgh PA 15213, E-mail: firstname.lastname@example.org.